Company Overview
About bit.bio
bit.bio is a synthetic biology company founded in 2016 as a spinout from the Luscher laboratory at the University of Cambridge, headquartered in Cambridge, United Kingdom. The company's core technology platform, opti-ox (optimized overexpression), enables the precise and highly reproducible reprogramming of human induced pluripotent stem cells (iPSCs) into virtually any human cell type — neurons, cardiomyocytes, hepatocytes, immune cells, and more — with a consistency and scalability that has historically been impossible to achieve with conventional differentiation protocols. This precision is achieved by engineering the transcription factor expression cassette into a defined genomic safe harbor site, ensuring every cell in a batch receives the same reprogramming instruction.
Business Model & Competitive Advantage
bit.bio raised £71M in a Series B funding round, with investors including Foresite Capital, Agilent Technologies, DCVC, and Atomico. The company's primary commercial offering is high-quality human cell products — sold under the ioCell brand — to pharmaceutical and biotech companies for drug discovery, disease modeling, and toxicology testing. By providing standardized, well-characterized human cells rather than animal cells or inconsistently derived human primary cells, bit.bio enables more predictive preclinical research and reduces the translatability gap between lab findings and clinical outcomes. This addresses one of the most persistent failure points in drug development: results that work in animal or inconsistent cell models but fail in human trials.
Competitive Landscape 2025–2026
bit.bio is also developing capabilities in cell therapy manufacturing — where the same opti-ox precision that produces research-grade cells could enable the manufacturing of allogeneic (off-the-shelf) cell therapies at the scale and consistency required for commercial pharmaceutical production. This positions bit.bio at the intersection of life science tools, drug discovery, and regenerative medicine manufacturing. The company competes with cell biology suppliers such as Thermo Fisher Scientific, Lonza, and ATCC, as well as specialist iPSC companies such as Fujifilm CDI and BlueRock Therapeutics.
Key Differentiators
Emerging Innovator
bit.bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare bit.bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from bit.bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim bit.bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention bit.bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →